Pharmacokinetics and biodistribution of 86Y-trastuzumab for 90Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI
S Palm, RM Enmon, C Matei, KS Kolbert… - Journal of Nuclear …, 2003 - Soc Nuclear Med
Preclinical biodistribution and pharmacokinetics of investigational radiopharmaceuticals are
typically obtained by longitudinal animal studies. These have required the sacrifice of …
typically obtained by longitudinal animal studies. These have required the sacrifice of …
Preclinical evaluation of 227Th-labeled and 177Lu-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts
N Abbas, ØS Bruland, EM Brevik… - Nuclear medicine …, 2012 - journals.lww.com
Objective The aim of the present study was to compare the biodistribution, normal tissue
toxicity, and therapeutic effect of two low-dose rate radioimmunoconjugates (RICs) in mice …
toxicity, and therapeutic effect of two low-dose rate radioimmunoconjugates (RICs) in mice …
Pharmacokinetics and Imaging of 212Pb-TCMC-Trastuzumab After Intraperitoneal Administration in Ovarian Cancer Patients
RF Meredith, J Torgue, MT Azure, S Shen… - Cancer Biotherapy …, 2014 - liebertpub.com
Purpose: Study distribution, pharmacokinetics, and safety of intraperitoneal (IP) 212Pb-
TCMC-trastuzumab in patients with HER-2-expressing malignancy. Experimental Design: IP …
TCMC-trastuzumab in patients with HER-2-expressing malignancy. Experimental Design: IP …
Targeted alpha therapy with 227Th-trastuzumab of intraperitoneal ovarian cancer in nude mice
H Heyerdahl, N Abbas, K Sponheim… - Current …, 2013 - ingentaconnect.com
The aim of the current study was to investigate the therapeutic effect of 227Th-
radioimmunotherapy on intraperitoneally growing human bioluminescent HER2 positive …
radioimmunotherapy on intraperitoneally growing human bioluminescent HER2 positive …
Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging
ECF Dijkers, JGW Kosterink… - Journal of nuclear …, 2009 - Soc Nuclear Med
The anti–human epidermal growth factor receptor 2 (HER2/neu) antibody trastuzumab is
administered to patients with HER2/neu-overexpressing breast cancer. Whole-body …
administered to patients with HER2/neu-overexpressing breast cancer. Whole-body …
Dose escalation and dosimetry of first-in-human α radioimmunotherapy with 212Pb-TCMC-trastuzumab
R Meredith, J Torgue, S Shen, DR Fisher… - Journal of Nuclear …, 2014 - Soc Nuclear Med
Our purpose was to study the safety, distribution, pharmacokinetics, immunogenicity, and
tumor response of intraperitoneal 212Pb-TCMC-trastuzumab (TCMC is S-2-(4 …
tumor response of intraperitoneal 212Pb-TCMC-trastuzumab (TCMC is S-2-(4 …
Radiobromination of humanized anti-HER2 monoclonal antibody trastuzumab using N-succinimidyl 5-bromo-3-pyridinecarboxylate, a potential label for immunoPET
E Mume, A Orlova, PU Malmström, H Lundqvist… - Nuclear medicine and …, 2005 - Elsevier
Combining the specificity of radioimmunoscintigraphy and the high sensitivity of PET in an in
vivo detection technique could improve the quality of nuclear diagnostics. Positron-emitting …
vivo detection technique could improve the quality of nuclear diagnostics. Positron-emitting …
Evaluation of 89Zr-pertuzumab in Breast Cancer Xenografts
BV Marquez, OF Ikotun, A Zheleznyak… - Molecular …, 2014 - ACS Publications
Pertuzumab is a monoclonal antibody that binds to HER2 and is used in combination with
another HER2–specific monoclonal antibody, trastuzumab, for the treatment of HER2+ …
another HER2–specific monoclonal antibody, trastuzumab, for the treatment of HER2+ …
Antitumor effects and normal-tissue toxicity of 111In-nuclear localization sequence-trastuzumab in athymic mice bearing HER-positive human breast cancer …
DL Costantini, K McLarty, H Lee, SJ Done… - Journal of Nuclear …, 2010 - Soc Nuclear Med
111In-nuclear localization sequence-trastuzumab is a radioimmunotherapeutic agent
consisting of trastuzumab modified with NLS peptides (CGYGPKKKRKVGG) and labeled …
consisting of trastuzumab modified with NLS peptides (CGYGPKKKRKVGG) and labeled …
A comparative evaluation of the chelators H4octapa and CHX-A ″-DTPA with the therapeutic radiometal 90Y
Objectives To compare the radiolabeling performance, stability, and practical efficacy of the
chelators CHX-A ″-DTPA and H 4 octapa with the therapeutic radiometal 90 Y. Methods …
chelators CHX-A ″-DTPA and H 4 octapa with the therapeutic radiometal 90 Y. Methods …